[email protected] | |
3275638434 | |
Paper Publishing WeChat |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Khorlan I. Itzhanova, Roza B. Seidakhmetova and Sergazy M. Adekenov
Full-Text PDF XML 314 Views
DOI:10.17265/2328-2150/2018.08.010
The mandatory preclinical safety evaluation is an
essential prerequisite to obtain the qualitative and effective
medicines. Due to the fact that drugs may reveal genotoxic properties, the
investigation of their mutagenic activity is an obligatory part of the
preclinical drug safety program. The aim of the research is to study mutagenic
properties of a new original immunomodulator Arglabin native in tablets in the
induced test of gene mutations (the Ames test) on Salmonella typhimurium strains. Materials and methods: Four strains of S. typhimurium TA98, TA100, TA1535, and
TA1537 were used to assess the mutagenicity in the Ames test. Results and
conclusions: No statistically
reliable dose-dependent increase in the number of revertant colonies of Salmonella typhimurium has been observed
in the presence of the given drug within the investigated dose ranges from 5.0
to 100.0 μg/mL for strains TA100 and TA1535, and from 5.0 to 250 μg/mL for
strains TA98 and TA1537 against the baseline of spantaneous mutations. Arglabin
native in tablets does not reveal a mutagenic activity within the studied dose
ranges on Salmonella typhimurium strains TA98, TA100, TA1535, TA1537.
Arglabin native, the Ames test, mutagenic properties.
Khorlan I. Itzhanova., et al. 2018. “Investigation of the Mutagenic Potential of Immunomodulator Arglabin Native in Tablets in the Ames Test.” Journal of Pharmacy and Pharmacology 6 (8): 790-795.